Pharvaris raises $80m Series C financing co-led by Viking Global Investors and General Atlantic

– SWITZERLAND, Zug –  Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the close of its oversubscribed $80 million Series C financing round co-led by Viking Global Investors and General Atlantic alongside Cormorant Asset Management.…

Talent4Boards
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.